- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Teva's $15B free drug opioid settlement might be a great deal in the long run: analyst | ||
| Do | CSL: Former exec stole 'thousands' of secret files before joining rival Pharming | ||
| Do | J&J, Amarin cardiovascular drugs are cost-effective, ICER says-but there's a catch | ||
| Do | Lawsuit-ridden J&J tumbles in annual listing of best global brands | ||
| Do | New CDMO, backed by private equity player, to manufacture biologics | ||
| Mi | Another hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes | ||
| Mi | Roche limits biosim damage to cancer blockbusters, but it's still early, execs warn | ||
| Mi | Teva, J&J make multibillion-dollar settlement offers as opioid trial gets going | ||
| Mi | Novo builds $40M wastewater plant then gives it away | ||
| Mi | Sanofi aims to save 1,100 jobs in Bangladesh by selling its local stake: report | ||
| Mi | FDA tags Torrent as key offender in production of tainted blood pressure meds | ||
| Mi | J&J wins reversal of $110M talc verdict, its 4th appeals win in Missouri | ||
| Di | Gilead elevates M&A architect Dickinson to CFO. Could more deals be next? | ||
| Di | Pfizer scrambles to fill void after Teva stops making chemo drug often given to children | ||
| Di | Johnson & Johnson's bridging its $2B patent cliff gap, with help from Stelara, Darzalex | ||
| Di | Merck and the machine: German pharma tests real-time platform to forestall drug shortages | ||
| Di | Sanofi U.S. plant sets new bar for biologics production | ||
| Di | Takeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino | ||
| Mo | AstraZeneca got past FluMist's efficacy woes, but now it's plagued by production problems | ||
| Mo | J&J, Bayer's Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization | ||
| Mo | Purdue, billionaire founders win temporary reprieve from lawsuits in hopes of reaching deal | ||
| Mo | FiercePharmaPolitics-PhRMA attacks Pelosi plan as CBO says it would lower spending; drugmakers raise more prices | ||
| 11.10. | Lilly scores FDA nod for new migraine drug Reyvow | ||
| 11.10. | ICER says AbbVie's Rinvoq for RA may be cost-effective but still questions the value of JAK class | ||
| 11.10. | Johnson & Johnson, besieged by lawsuits, could be a steal for investors: analyst |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
